fda warning letter peptides 2025 september September 8, 2025 - fda-warning-bpc-157-peptide-safety letter FDA Warning Letters for Peptides: A September 2025 Roundup and Implications

fda-peptide-warning-2025-october The FDA has significantly increased its enforcement actions concerning peptides and GLP-1 related drugs, with a notable surge in warning letters issued throughout September 2025. This intensified regulatory scrutiny reflects the agency's commitment to ensuring drug safety, proper labeling, and adherence to manufacturing standards. As of September 2025, the FDA's focus has been particularly sharp on companies involved in the compounding and marketing of these substances, leading to numerous alerts and official communications.

One of the key areas of concern for the FDA involves the marketing and advertising of peptide-based products. Several pharmaceutical companies, including Novo Nordisk Inc. and Eli Lilly and Company, have received warning letters in September 2025 regarding the promotion of their GLP-1 drugs.Generic Drugs, Food and Drug Administration (FDA), FDA ... For instance, Novo Nordisk's Ozempic and Eli Lilly's Mounjaro and Zepbound® (tirzepatide) injection have been highlighted in warning letters for issues related to their approved indications and associated risks, such as the boxed warning regarding the risk of pancreatitis and thyroid C-cell tumors. The FDA's directives emphasize the importance of accurate risk disclosure and preventing misleading direct-to-consumer pharmaceutical promotionsFDA “Cuts Red Tape” on Clinical Decision Support ....

Furthermore, the FDA has been actively addressing the practices of compounding pharmacies.Generic Drugs, Food and Drug Administration (FDA), FDA ... In September 2025, numerous warning letters were dispatched to facilities involved in the compounding of peptides, particularly those mimicking the effects of GLP-1 drugs like semaglutideIn2025, theFDAapproved 46 novel drugs, including four TIDEs (onepeptide, three oligonucleotides, and one antibody drug conjugate containingpeptideas a .... These letters often cite violations of Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act (FDCA), which govern the conditions for compounding drug products. The agency's actions aim to curb the preparation of custom peptide medications outside of established regulatory frameworks, even for individual patients with prescriptionsEli Lilly and Company - 716475 - 09/09/2025. This has led to discussions about the legal battles surrounding the FDA's oversight on compounded peptides.

The FDA's proactive stance is also evident in its establishment of a "green list" import alert, designed to prevent the entry of potentially dangerous GLP-1 products into the United States.2026年1月8日—FDAramps up enforcement on GLP-1s,peptides, RUO labeling, and compounding practices. See how 503A and 503B facilities are affected. This initiative, alongside the issuance of over 50 warning letters to GLP-1 drug compounders and manufacturers by October 1, 2025, underscores a broad effort to tighten control over the supply chain and product integrity. The FDA's enforcement activities in advertising and promotion are also being closely monitored, with a review of publicly available warning letters and untitled letters indicating a significant increase in such actions throughout 2025Novo Nordisk Inc. - 716495 - 09/09/2025.

Looking ahead, the FDA's regulatory landscape for peptides and related therapeutics continues to evolve.2026年1月2日—The USFDAapproved 46 new drugs in2025, despite a tumultuous year at the regulatory agency. While the FDA approved 46 novel drugs in 2025, including peptide-containing medications, the agency's commitment to robust oversight remains paramount2024年10月1日—InSeptember2023, the Food and Drug Administration (FDA) placed severalpeptidebulk drug substances on Category 2 of theFDA'sinterim .... The FDA has also been involved in removing certain peptide bulk drug substances from its purview, indicating a dynamic regulatory environment.2024年10月1日—InSeptember2023, the Food and Drug Administration (FDA) placed severalpeptidebulk drug substances on Category 2 of theFDA'sinterim ... Companies operating within the peptide and GLP-1 space must remain vigilant, ensuring full compliance with FDA regulations to avoid potential warning letters, alerts, and other enforcement actions.2025年9月8日—WARNING LETTER.September 8, 2025. RE: 715218. Dear Seann Gloss: This letter is to advise you that the United States Food and Drug ... The FDA's ongoing review and issuance of warning letters serve as a critical reminder of the importance of rigorous adherence to safety and manufacturing standards in the pharmaceutical industry, particularly for novel therapeutic classes like peptides.